ARTELO BIOSCIENCES, INC. IPO Filing Research

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1 and marks the registration effective.

2026-05-19 · 9999999995-26-001705

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

First tracked pre-IPO filing for this issuer.

50,858 shares · Gross proceeds $451,527

Common Stock · Exchange Nasdaq · Ticker ARTL · Underwriters R.F. Lafferty & Co., Inc.

2026-05-18 · 0001640334-26-000926

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows S-1/A and confirms the priced prospectus.

9,820,294 shares · Gross proceeds $21,508,909

Common Stock · Exchange Nasdaq Capital Market · Ticker ARTL · Warrants exercisable at $0.001, $3.20, and $4.3125 per share with beneficial ownership limits · Selling stockholders only · Use of proceeds Debt repayment, working capital, and acquisitions

2026-04-16 · 0001640334-26-000761

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1 and marks the registration effective.

2026-04-15 · 9999999995-26-001202

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows S-1 in the pre-IPO sequence.

9,820,294 shares · Gross proceeds $21,508,909

Common · Exchange Nasdaq · Ticker ARTL · Pre-Funded Warrants at $0.001 per share, Common Warrants at $3.20 per share, Placement Agent Warrants at $4.3125 per share · Selling stockholders only · Use of proceeds to receive proceeds from warrant exercises

2026-04-07 · 0001640334-26-000670

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

First tracked pre-IPO filing for this issuer.

Artelo Biosciences, Inc. filed a Notice of Effectiveness for its S-1 registration statement on March 30, 2026, following a prior request to withdraw its earlier S-1 filing (File No. 333-294506) on March 27, 2026. The company confirmed it does not intend to proceed with the contemplated securities offering and stated no securities were issued or sold under the withdrawn registration.

2026-03-30 · 9999999995-26-001002

RW withdrawn

Withdrawal request

Issuer requested withdrawal of the registration statement.

Follows S-1 and ends the active registration process.

Artelo Biosciences, Inc. has submitted a Form RW to withdraw its previously effective Registration Statement on Form S-1 (File No. 333-294506), which was filed on March 20, 2026. The company confirms no securities were issued or sold under the registration and cites its decision not to pursue the contemplated offering. The withdrawal request includes a request to credit fees paid to the SEC for future use.

2026-03-27 · 0001640334-26-000558

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1 and marks the registration effective.

Artelo Biosciences, Inc. has filed an effective registration statement (EFFECT) for its IPO, offering up to 1,641,587 shares of common stock, pre-funded warrants, and placement agent warrants. The offering is on a best-efforts basis with an assumed public price of $7.31 per share, based on the company's recent Nasdaq closing price. The company engaged Craft Capital Management LLC as the exclusive placement agent, with fees including 7% of gross proceeds and 4% in placement agent warrants. The offering is expected to close by March 31, 2026, with no minimum offering requirement.

2026-03-25 · 9999999995-26-000932

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows S-1/A in the pre-IPO sequence.

4,273,519 shares

Common Stock · Exchange Nasdaq · Ticker ARTL · Pre-funded warrants exercisable at $0.003 per share · Selling stockholders only · Use of proceeds Potential proceeds from future sales to Square Gate up to $50,000,000 · Underwriters Square Gate Capital Master Fund, LLC - Series 5

Artelo Biosciences, Inc. filed an S-1 registration statement for the resale of up to 4,273,519 shares of common stock by Square Gate Capital Master Fund, LLC - Series 5 under an Equity Purchase Agreement. The filing outlines two components: commitment shares (including pre-funded warrants) and put shares issued at a discount to the market price. Unlike the previous S-1/A, which focused on an initial offering of 1.6 million shares and pre-funded warrants, this filing emphasizes the resale structure and potential $50 million in gross proceeds from company-led sales. The company is not directly involved in the resale but may benefit from future sales under the ELOC Purchase Agreement.

2026-03-24 · 0001640334-26-000543

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

Price $7.31 · 1,641,587 shares

Common Stock · Exchange Nasdaq · Ticker ARTL · Pre-funded warrants to purchase common stock at $0.001 per share and placement agent warrants for 4% of shares sold · Underwriters Craft Capital Management LLC

Artelo Biosciences, Inc. is conducting a primary offering of 1,641,587 shares of common stock, pre-funded warrants, and placement agent warrants, differing from the previous S-1 which focused on a resale offering by Square Gate Capital. The current filing includes detailed terms for the offering, including a public price of $7.31 per share, placement agent fees, and warrants. The company also highlights risks related to the lack of a market for pre-funded warrants and uncertainty in offering proceeds.

2026-03-24 · 0001640334-26-000540

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1 filing.

Price $7.31 · 3,414,501 shares

Common Stock · Exchange Nasdaq Capital Market · Ticker ARTL · Pre-funded warrants to purchase common stock at $0.001 per share, exercisable immediately · Use of proceeds Working capital and general corporate purposes · Underwriters Craft Capital Management LLC

Artelo Biosciences, Inc. is conducting an IPO offering up to 1,641,587 shares of common stock at an assumed public price of $7.31, with pre-funded warrants and placement agent warrants. The offering is subject to a closing date of March 31, 2026, and includes provisions for delivery versus payment. The company emphasizes risks related to market volatility, uncertain proceeds, and lack of liquidity for warrants.

2026-03-23 · 0001640334-26-000515

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows DRS in the pre-IPO sequence.

Price $7.31 · 1,641,587 shares

Common Stock · Exchange Nasdaq · Ticker ARTL · Pre-funded warrants to purchase common stock at $0.001 per share and placement agent warrants · Use of proceeds Use of proceeds to be disclosed in prospectus · Flags best_efforts · Underwriters Craft Capital Management LLC

Artelo Biosciences, Inc. is conducting an IPO offering up to 1,641,587 shares of common stock at an assumed public price of $7.31, along with pre-funded warrants and placement agent warrants. The offering is on a best-efforts basis with no minimum requirements, and the company has engaged Craft Capital Management LLC as the exclusive placement agent. The filing highlights potential dilution, lack of established markets for pre-funded warrants, and risks related to the offering's pricing and structure.

2026-03-20 · 0001640334-26-000502

DRS filed

Draft registration statement

Draft registration filed confidentially before the public launch.

Begins the tracked draft filing sequence after EFFECT.

Artelo Biosciences, Inc. filed a draft registration statement (DRS) for a potential IPO, registering up to 29,293,631 shares of common stock for resale by Square Gate Capital Master Fund, LLC - Series 5. The company is not receiving proceeds from the resale but may access up to $50 million via the ELOC Purchase Agreement. The stock is listed on Nasdaq under 'ARTL,' with a recent closing price of $1.14. The filing includes risk factors, a plan of distribution, and details about the ELOC agreement terms.

2026-03-09 · 0001640334-26-000403

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1 and marks the registration effective.

Artelo Biosciences, Inc. has filed an S-1 registration statement for the resale of up to 899,972 shares of common stock by selling securityholders. The shares include those from convertible notes, $6.24 warrants, and $3.40 warrants. The company is not receiving proceeds from the resale but may receive net proceeds from warrant exercises. A 1-for-6 reverse stock split effective June 13, 2025, adjusted all share and per-share amounts. The filing includes details about the company's capital structure, risk factors, and distribution plans.

2025-12-02 · 9999999995-25-003484

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows DRS in the pre-IPO sequence.

899,972 shares

Common Stock, par value $0.001 per share · Exchange Nasdaq Capital Market · Ticker ARTL · Warrants exercisable at $6.24 and $3.40 per share · Selling stockholders only · Use of proceeds Proceeds from warrant exercises for cash · Flags warrants

Artelo Biosciences, Inc. filed an S-1 registration statement for the resale of up to 899,972 shares of common stock by selling securityholders, including shares from convertible notes and warrants issued in private placements. The filing includes a 1-for-6 reverse stock split adjustment effective June 13, 2025, and notes that the company will not receive proceeds from the resale but may receive net proceeds from warrant exercises. The company is a smaller reporting company with risks related to its high-risk investment profile and potential SEC scrutiny of selling securityholders as underwriters.

2025-11-17 · 0001640334-25-002154

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

Price $4.40 · 441,210 shares · Gross proceeds $1,999,985

Common Stock · Exchange NASDAQ · Ticker ARTL · Over-allotment 68,181 · 13,335 Pre-Funded Warrants exercisable at $0.001 per share · Underwriters R.F. Lafferty & Co., Inc.

2025-10-01 · 0001640334-25-001763

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows S-1 and confirms the priced prospectus.

Common Stock and Pre-funded Warrants to Purchase up to [ ] Shares · Exchange Nasdaq · Ticker ARTL · Pre-funded Warrants to purchase up to [ ] shares at $0.001 exercise price · Flags warrants · Underwriters R.F. Lafferty & Co., Inc.

2025-09-30 · 0001640334-25-001749

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

Gross proceeds $451,527

Common Stock · Exchange Nasdaq · Ticker ARTL · Use of proceeds Proceeds from ATM offering used for general corporate purposes. · Underwriters R.F. Lafferty & Co., Inc.

2025-09-30 · 0001640334-25-001747

DRS filed

Draft registration statement

Draft registration filed confidentially before the public launch.

Begins the tracked draft filing sequence after EFFECT.

Artelo Biosciences, Inc. is registering a potential offering of up to [ ] units, each consisting of one share of common stock or pre-funded warrant and one warrant. The filing includes provisions for pre-funded units to address beneficial ownership limits, with warrants exercisable at $[ ] and expiring five years from issuance. The offering is structured on a best-efforts basis without a minimum threshold, and the company notes no established market for the warrants. The filing remains confidential and has not been publicly submitted.

2025-09-29 · 0001640334-25-001740

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

Price $4.40 · 640,924 shares · Gross proceeds $2,999,958

Common Stock · Exchange Nasdaq · Ticker ARTL · Over-allotment 102,272 · Pre-funded warrants exercisable at $0.001 per share · Use of proceeds General corporate purposes · Underwriters R.F. Lafferty & Co., Inc.

Artelo Biosciences, Inc. is offering 640,924 shares of common stock at $4.40 per share and pre-funded warrants to purchase 40,894 shares at $0.001 per share. The offering includes underwriting discounts and details on proceeds, with R.F. Lafferty & Co., Inc. as the sole book runner. The company notes risks associated with its securities, including market volatility and lack of trading liquidity for pre-funded warrants.

2025-09-05 · 0001640334-25-001629

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

Common Stock, Pre-Funded Warrants to Purchase up to [ ] Shares of Common Stock · Exchange Nasdaq · Ticker ARTL · Pre-funded warrants exercisable at $0.001 per share, purchased by investors who would otherwise exceed 4.99% beneficial ownership threshold · Underwriters R.F. Lafferty & Co., Inc.

Artelo Biosciences, Inc. is offering up to [ ] shares of common stock and [ ] pre-funded warrants to purchase additional shares, with the warrants exercisable at $0.001 per share. The offering is underwritten by R.F. Lafferty & Co., Inc., with the common stock listed on Nasdaq under 'ARTL.' The filing updates previous disclosures, focusing on the structure of the offering and underwriting terms.

2025-09-04 · 0001640334-25-001624

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows S-1/A and confirms the priced prospectus.

Gross proceeds $3,451,527

Common Stock · Exchange Nasdaq · Ticker ARTL

Artelo Biosciences, Inc. filed a 424B5 prospectus supplement to reduce the maximum aggregate gross sales price of its at-the-market (ATM) offering of common stock from $6.5 million to $3,451,527, effective September 4, 2025. The update reflects $451,526.95 in shares already sold under the previous $6.5 million threshold. The Sales Agreement with R.F. Lafferty & Co., Inc. remains active, with the company emphasizing compliance with Form S-3 regulations limiting sales to one-third of its public float. The stock is listed on Nasdaq under 'ARTL,' with a recent closing price of $8.76 as of September 3, 2025.

2025-09-04 · 0001640334-25-001622

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows S-1/A and confirms the priced prospectus.

Gross proceeds $6,500,000

Common Stock · Exchange Nasdaq Capital Market · Ticker ARTL · Underwriters R.F. Lafferty & Co., Inc.

The current filing is a prospectus supplement for Artelo Biosciences, Inc.'s at-the-market offering of up to $6.5M in common stock via R.F. Lafferty & Co., Inc. as exclusive sales agent. The offering is structured under a Sales Agreement allowing sales on Nasdaq at market prices, with a 2% commission to the Sales Agent. The supplement updates the existing prospectus dated July 7, 2023, and includes details about distribution terms, market value calculations, and risk disclosures.

2025-07-18 · 0001640334-25-001239

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1 and marks the registration effective.

Artelo Biosciences, Inc. filed an S-1 registration statement effective July 17, 2025, relating to the resale of up to 920,092 shares of common stock by selling securityholders. The filing includes shares issued in a June 2025 private placement, along with warrants and pre-funded warrants. The company did not receive proceeds from the resale but may receive proceeds from warrant exercises. A 1-for-6 reverse stock split was effective June 13, 2025, adjusting all share and per-share amounts. The stock is listed on Nasdaq under 'ARTL' with a recent closing price of $28.50.

2025-07-17 · 9999999995-25-002274

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows EFFECT in the pre-IPO sequence.

920,092 shares

Common Stock · Exchange Nasdaq Capital Market · Ticker ARTL · Each Share or Pre-Funded Warrant was issued with two $5.82 Warrants and one $10.00 Warrant · Warrants exercisable at $5.82 and $10.00 per share · Selling stockholders only · Use of proceeds Proceeds from warrant exercises will be used for general corporate purposes

Artelo Biosciences, Inc. filed an S-1 registration statement for the resale of up to 920,092 shares of common stock by selling securityholders. The shares include those from a June 2025 private placement, along with warrants and pre-funded warrants. The company underwent a 1-for-6 reverse stock split in June 2025, effective June 13, 2025. Artelo will not receive proceeds from the resale but will benefit from warrant exercises. The filing emphasizes risks related to the company's early-stage development and reliance on future financing.

2025-07-11 · 0001640334-25-001190

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

The filing confirms the effectiveness of Artelo Biosciences' S-3 registration statement, enabling the sale of up to 15,000,000 shares of common stock by Lincoln Park Capital Fund, LLC. The company is not receiving proceeds from the sale, which is structured under a May 2022 purchase agreement. The shares may be sold at market prices or through negotiated transactions, with Lincoln Park acting as an underwriter.

2023-07-14 · 9999999995-23-002100

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows S-1/A and confirms the priced prospectus.

15,000,000 shares

common · Exchange Nasdaq Capital Market · Ticker ARTL · Selling stockholders only · Use of proceeds Proceeds will go to the selling stockholder; no proceeds to the company · Underwriters Lincoln Park Capital Fund, LLC

Arterlo Biosciences, Inc. filed a 424B3 prospectus supplement relating to the offer and sale of up to 15,000,000 shares of common stock by Lincoln Park Capital Fund, LLC (the 'selling stockholder'). The shares are being offered pursuant to a May 13, 2022 purchase agreement with Lincoln Park, which acts as an underwriter. The company will not receive proceeds from the sale, and the shares will be sold at prevailing market prices or through negotiated transactions. The filing emphasizes the high-risk nature of investing in the company's securities.

2022-06-02 · 0001640334-22-001167

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1 and marks the registration effective.

Artelo Biosciences, Inc. filed an S-1 registration statement effective May 31, 2022, registering up to 15,000,000 shares of common stock offered by Lincoln Park Capital Fund, LLC. The company is not receiving proceeds from the sale, which will be managed by the selling stockholder. The filing includes details about the Lincoln Park transaction, risk factors, and compliance with reduced disclosure requirements as a smaller reporting company.

2022-05-31 · 9999999995-22-001644

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows EFFECT in the pre-IPO sequence.

15,000,000 shares

common stock · Exchange Nasdaq Capital Market · Ticker ARTL · Selling stockholders only · Use of proceeds The company will not receive any proceeds from the sale of shares by the selling stockholder. · Underwriters Lincoln Park Capital Fund, LLC

Artelo Biosciences, Inc. filed an S-1 registration statement to offer up to 15,000,000 shares of common stock through Lincoln Park Capital Fund, LLC (the 'selling stockholder'). The company is not receiving proceeds from the sale, which will be conducted under a purchase agreement dated May 13, 2022. The offering replaces a prior at-the-market program with Ladenburg Thalmann & Co. Inc., which was outlined in a 424B5 filing. The company remains a smaller reporting company and has elected reduced disclosure requirements.

2022-05-16 · 0001640334-22-001028

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows S-1 and confirms the priced prospectus.

Gross proceeds $20,500,000

Common Stock · Exchange Nasdaq Capital Market · Ticker ARTL · Underwriters Ladenburg Thalmann & Co. Inc.

Artelo Biosciences, Inc. filed a 424B5 prospectus supplement to register up to $20.5 million in common stock offerings through Ladenburg Thalmann & Co. Inc. as the exclusive sales agent. The offering is structured as an at-the-market program under a Sales Agreement dated April 9, 2021, with a 3% commission for the sales agent. The supplement updates the previous prospectus dated February 3, 2020, and includes details on market value, distribution plans, and risk disclosures.

2021-04-09 · 0001640334-21-000819

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B4 and marks the registration effective.

Artelo Biosciences, Inc. received effectiveness for a Post-Effective Amendment (POS AM) to its securities registration statement, indicating regulatory approval for potential public offering activities. The filing date is January 21, 2021, with a new file number (333-249083) compared to the previous filing (333-230658).

2021-01-21 · 9999999995-21-000211

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

Artelo Biosciences, Inc. filed a Notice of Effectiveness for its securities offering, confirming the availability of 8,800,000 units consisting of common stock and warrants. The offering, underwritten by Ladenburg Thalmann & Co. Inc., includes a public price of $0.75 per unit, with proceeds to the company before expenses at $0.69 per unit. The prospectus highlights risks related to the lack of a trading market for warrants, clinical trial uncertainties, and pandemic-related delays.

2021-01-21 · 9999999995-21-000207

424B4 priced

Final prospectus

Final prospectus filed after pricing with final deal terms.

Follows EFFECT and confirms the priced prospectus.

Price $0.75 · 8,800,000 shares · Gross proceeds $6,600,000

Common Stock · Exchange Nasdaq Capital Market · Ticker ARTL · Over-allotment 1,320,000 · Each Unit consists of one share of common stock and one warrant to purchase one share of common stock · Warrants to purchase one share at $0.75, exercisable after stockholder approval, expiring 5 years from issuance · Use of proceeds Proceeds before expenses to the company are $6,072,000 · Flags units, warrants · Underwriters Ladenburg Thalmann & Co. Inc.

Artelo Biosciences, Inc. is offering 8,800,000 units, each consisting of one share of common stock and one warrant to purchase a share at $0.75. The company is a clinical-stage biopharmaceutical firm focused on modulating endogenous signaling pathways, including the endocannabinoid system. It has three product candidates in development, with risks including clinical trial delays, lack of market liquidity for warrants, and dependence on regulatory approvals.

2020-10-13 · 0001640334-20-002532

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1/A and marks the registration effective.

Artelo Biosciences, Inc. filed an amendment to its S-1 registration statement, which became effective on October 8, 2020. The amendment is an 'exhibits-only' filing, indicating no changes to the prospectus itself. The company remains in the process of registering securities under the Securities Act of 1933, with estimated issuance and distribution expenses totaling $400,000.

2020-10-08 · 9999999995-20-002794

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

244,033 shares

Artelo Biosciences, Inc. filed an S-1/A amendment to its registration statement for an IPO, focusing on adding exhibits and revising legal opinions. The filing includes details about securities issuance expenses, indemnification provisions for directors/officers, and recent private placements. The prospectus remains unchanged, with the amendment primarily addressing procedural and legal documentation.

2020-10-08 · 0001640334-20-002503

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

244,033 shares

Artelo Biosciences, Inc. filed an S-1/A amendment to its registration statement, characterizing the filing as an 'exhibits-only' submission. The amendment includes Part II information, signature pages, and exhibits, with the prospectus unchanged. The company outlines offering expenses, indemnification provisions for directors/officers, and details of recent private securities sales. The filing reflects ongoing preparatory steps for a potential public offering, with no material changes to the core offering structure compared to prior disclosures.

2020-10-07 · 0001640334-20-002484

FWP supplemental

Free writing prospectus

Prospectus supplement or marketing filing that often updates active offering terms.

First tracked pre-IPO filing for this issuer.

Artelo Biosciences, Inc. is offering 6,395,348 units consisting of common stock and warrants, with a public offering price of $0.86 per unit. The offering is underwritten by Ladenburg Thalmann & Co. Inc., with warrants exercisable after shareholder approval of increased authorized shares. The filing includes preliminary prospectus details, risk disclosures, and underwriting terms.

2020-10-06 · 0001640334-20-002473

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1 filing.

Price $0.86 · 6,395,348 shares · Gross proceeds $6,325,000

Common Stock · Exchange Nasdaq Capital Market · Ticker ARTL · Each Unit consists of one share of Common Stock and one warrant to purchase one share of Common Stock · Warrants exercisable at 125% of the public offering price, exercisable after stockholder approval of increased authorized shares, expiring 5 years from prospectus date · Use of proceeds Working capital and general corporate purposes · Flags units, warrants · Underwriters Ladenburg Thalmann & Co. Inc.

Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments targeting endogenous signaling pathways, including the endocannabinoid system. The company is advancing three product candidates, including ART27.13 for cancer-related anorexia, ART26.12 as a FABP5 inhibitor, and ART12.11 for CBD cocrystal. The S-1/A filing outlines an offering of 6,395,348 units consisting of common stock and warrants, with a public offering price of $0.86 per unit. The company faces uncertainties due to the COVID-19 pandemic impacting clinical trial timelines and lacks revenue, relying on equity financing.

2020-10-06 · 0001640334-20-002471

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows EFFECT in the pre-IPO sequence.

Gross proceeds $4,000,000

Common Stock · Exchange Nasdaq Capital Market · Ticker ARTL · Each Unit consists of one share of Common Stock and one warrant to purchase one share of Common Stock · Warrants exercisable at 125% of the public offering price, exercisable after stockholder approval of share increase or reverse split, expires in 5 years · Use of proceeds Working capital · Flags units, warrants · Underwriters Ladenburg Thalmann & Co. Inc.

Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments targeting the endocannabinoid system (ECS). The company is conducting Phase 1b/2a trials for ART27.13 (cancer-related anorexia), late pre-clinical studies for ART26.12 (cancer therapeutic), and advancing ART12.11, a CBD cocrystal formulation. The S-1 filing outlines an IPO offering units consisting of common stock and warrants, underwritten by Ladenburg Thalmann & Co. Inc., with a proposed maximum offering price of $4 million. The company highlights risks related to clinical trial uncertainties, regulatory approval, and the impact of the COVID-19 pandemic on timelines.

2020-09-28 · 0001640334-20-002415

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

Gross proceeds $2,249,412

Common Stock · Exchange Nasdaq Capital Market · Ticker ARTL · Flags emerging_growth_company · Underwriters Maxim Group LLC

Artelo Biosciences, Inc. filed a prospectus supplement (No. 3) for an at-the-market offering of up to $2,249,412 in common stock through Maxim Group LLC as exclusive sales agent. The filing updates the offering limit from a previous $1.475 million, reflects prior sales of 1,023,133 shares generating $1.474 million, and notes the company's emerging growth status with reduced disclosure requirements.

2020-07-14 · 0001640334-20-001759

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows S-1/A and confirms the priced prospectus.

Gross proceeds $1,475,000

Common Stock, par value $0.001 per share · Exchange Nasdaq Capital Market · Ticker ARTL · Underwriters Maxim Group LLC

Artelo Biosciences, Inc. is offering up to $1,475,000 in common stock through Maxim Group LLC as the exclusive sales agent under an at-the-market offering program. This prospectus supplement reflects a reduction in the aggregate gross sales price compared to the previous filing, which had an offering limit of $3 million. The company remains an emerging growth company with reduced disclosure requirements.

2020-04-15 · 0001640334-20-000837

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows S-1/A and confirms the priced prospectus.

Gross proceeds $3,000,000

Common · Exchange Nasdaq Capital Market · Ticker ARTL · Use of proceeds working capital · Underwriters Maxim Group LLC

Artelo Biosciences, Inc. filed a 424B5 prospectus supplement to register the issuance of up to $3.0 million in common stock through Maxim Group LLC as the exclusive sales agent. The offering is structured as an 'at-the-market' program under an equity distribution agreement, with commission rates of 2.0% for the first $2.0 million and 3.0% for the next $1.0 million. The company, listed on Nasdaq, is an emerging growth company with reduced disclosure requirements. The supplement references risk factors and incorporates documents by reference.

2020-04-14 · 0001640334-20-000811

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

Artelo Biosciences, Inc. received effectiveness for a registration statement on April 10, 2020, following an earlier effectiveness notice on February 3, 2020. The current filing relates to a post-effective amendment (POS AM) compared to the previous S-3 form, indicating potential updates to the registration statement. The company's CIK and name remained consistent between filings.

2020-04-10 · 9999999995-20-000720

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

Artelo Biosciences, Inc. filed an S-3 registration statement that became effective on February 3, 2020. This follows a prior S-3 filing effective December 20, 2019, with the same CIK number. The filings relate to shelf registration of securities, but no specific offering details are provided in the text.

2020-02-03 · 9999999995-20-000214

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

Artelo Biosciences, Inc. filed an S-3 registration statement effective December 20, 2019, for a public offering of 1,300,813 units consisting of common stock and warrants. The offering includes a $6.15 per unit public price, with underwriters Maxim Group LLC and Joseph Gunnar & Co. managing the sale. The company focuses on endocannabinoid system modulation, with pipeline candidates targeting cancer-related anorexia and FABP5 inhibition. The filing highlights risks related to clinical trials, regulatory approvals, and market competition.

2019-12-20 · 9999999995-19-002888

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B4 and marks the registration effective.

The filing confirms the effectiveness of Artelo Biosciences, Inc.'s S-3 registration statement on December 20, 2019, allowing the company to offer securities under a shelf registration. No substantive changes or new disclosures are evident from the provided text, which appears to be a standard notice of effectiveness with formatting and header information.

2019-12-20 · 9999999995-19-002879

424B4 priced

Final prospectus

Final prospectus filed after pricing with final deal terms.

Follows EFFECT and confirms the priced prospectus.

Price $6.15 · 1,300,813 shares · Gross proceeds $8,000,000

Common Stock · Exchange NASDAQ · Ticker ARTL · Over-allotment 195,121 · Each Unit consists of one Share of Common Stock and one Warrant · Warrants to purchase one Share of Common Stock at $6.4575 per share · Use of proceeds Proceeds to the company before expenses were $7,360,000 · Flags units, warrants · Underwriters Maxim Group LLC, Joseph Gunnar & Co.

Artelo Biosciences, Inc. is conducting a firm commitment public offering of 1,300,813 units, each consisting of one share of common stock and one warrant. The offering price is $6.15 per unit, with proceeds netting $5.658 per unit. The company transitioned from OTCQB to Nasdaq Capital Market listing, effective June 21, 2019. As an emerging growth company under the JOBS Act, it benefits from reduced reporting requirements. A reverse stock split of 1-for-8 was implemented on June 20, 2019.

2019-06-25 · 0001640334-19-001225

8-A12B effective

Exchange Act registration

Registration filed to list the securities under the Exchange Act ahead of trading.

First tracked pre-IPO filing for this issuer.

Artelo Biosciences, Inc. filed a Form 8-A12B to register its common stock and warrants on The Nasdaq Stock Market LLC. The filing incorporates by reference the securities description from its earlier S-1 registration statement, focusing on the company's securities structure and listing requirements. No new operational or financial details are provided beyond the registration framework.

2019-06-21 · 0001640334-19-001191

CERT inactive

CERT

Pre-IPO filing captured from the SEC submission timeline.

First tracked pre-IPO filing for this issuer.

Artelo Biosciences, Inc. filed a CERT form to register certain classes of securities, building on prior registration efforts outlined in its 8-A12B filing. The current filing focuses on registering common stock and warrants, aligning with previous disclosures about its capital structure and securities offerings.

2019-06-21 · 0001354457-19-000327

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1/A and marks the registration effective.

Artelo Biosciences, Inc. filed a Notice of Effectiveness for its S-1 registration statement on June 20, 2019, confirming the effectiveness of its IPO. The offering consists of 1,388,888 units, each containing one share of common stock and one warrant to purchase additional shares at $7.56 per share, exercisable for five years. The company, an emerging growth company under the JOBS Act, plans to list on the Nasdaq Capital Market. The offering includes underwriter warrants and is managed by Maxim Group LLC as the sole book-runner and Joseph Gunnar & Co. as co-manager.

2019-06-20 · 9999999995-19-001390

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

325,383 shares

Common Stock · Exchange NASDAQ

Artelo Biosciences, Inc. filed an S-1/A amendment to its registration statement for an IPO, focusing on updated disclosures around securities issuance, expenses, and recent private placements. The filing includes detailed information on prior equity offerings, indemnification policies, and legal opinions, with an emphasis on compliance with SEC regulations. The company has conducted multiple private placements (Series A-E) and outlines expenses related to the IPO, including legal, accounting, and underwriting fees.

2019-06-20 · 0001640334-19-001174

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

1,388,888 shares · Gross proceeds $11,500,000

Common Stock · Exchange OTCQB · Ticker ARTL · Over-allotment 208,333 · Units consisting of one share of Common Stock and one warrant · Warrants to purchase Common Stock at $7.56 per share (105% of unit price) exercisable 6 months post-effectiveness for 5 years · Use of proceeds For working capital and general corporate purposes · Underwriters Maxim Group LLC, Joseph Gunnar & Co.

Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments to modulate the endocannabinoid system (ECS), including a proprietary CBD cocrystal with improved pharmaceutical properties. The company is offering 1,388,888 units consisting of common stock and warrants, with an anticipated listing on the Nasdaq Capital Market. The offering includes underwriter warrants and is structured to fund clinical trials for programs like ART27.13 (cancer-related anorexia) and ART26.12 (FABP5 inhibitor). The company is an emerging growth company with a pipeline targeting unmet medical needs.

2019-06-10 · 0001640334-19-001091

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

1,388,888 shares

Common Stock · Exchange Nasdaq Capital Market · Ticker ARTL · Over-allotment 416,666 · 1,388,888 warrants to purchase common stock · Use of proceeds Proceeds to be used for general corporate purposes · Flags warrants · Underwriters Maxim Group LLC, Joseph Gunnar & Co.

Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments targeting the endocannabinoid system (ECS), including a proprietary CBD cocrystal (ART12.11) and two in-licensed programs: ART27.13 for cancer-related anorexia and ART26.12 for FABP5 inhibition. The company is offering 1,388,888 shares of common stock and warrants to raise capital, with underwriters Maxim Group LLC and Joseph Gunnar & Co. The filing highlights its pipeline progress, regulatory strategies, and risks associated with clinical trials and market competition.

2019-05-31 · 0001640334-19-001007

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1 filing.

1,388,888 shares · Gross proceeds $11,500,000

Common Stock, $0.001 par value per share · Exchange Nasdaq Capital Market · Ticker ARTL · Over-allotment 416,666 · Warrants to purchase common stock exercisable at 110% of public offering price, 8% of shares sold, 5-year term · Flags warrants · Underwriters Maxim Group LLC

Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for the endocannabinoid system (ECS), including a proprietary CBD cocrystal with improved pharmaceutical properties. The company is advancing two in-licensed programs: ART27.13 for cancer-related anorexia and ART26.12 as an FABP5 inhibitor for oncology. The S-1/A filing reflects updates to the offering, including a reverse stock split, revised registration fees, and details about underwriter warrants. The company seeks to raise $24.6 million through common stock and warrants, with plans to list on the Nasdaq Capital Market.

2019-05-29 · 0001640334-19-001003

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows EFFECT in the pre-IPO sequence.

Common Stock · Exchange Nasdaq Capital Market · Ticker ARTL · Warrants to purchase common stock exercisable at 110% of the public offering price, 8% of the shares sold, 6-month lock-up, 3-year term · Use of proceeds Working capital and general corporate purposes · Underwriters Maxim Group, LLC

Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments targeting the endocannabinoid system (ECS), including a proprietary CBD cocrystal (ART12.11) and two in-licensed programs: ART27.13 for cancer-related anorexia and ART26.12 as an FABP5 inhibitor. The company is offering up to $15.88 million in common stock and warrants, with Maxim Group, LLC as the exclusive placement agent. Artelo is an emerging growth company under the JOBS Act and anticipates listing on the Nasdaq Capital Market. The offering includes risks related to clinical trial outcomes, regulatory approval, market competition, and potential dilution.

2019-04-01 · 0001640334-19-000498

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1 and marks the registration effective.

Artelo Biosciences, Inc. filed an S-1 registration statement for 2,426,424 shares of common stock, including 1,213,212 shares from warrant exercises and 1,213,212 private placement shares, to be sold by existing stockholders. The filing became effective on October 5, 2018, with no proceeds going to the company. The stock is quoted on the OTCQB under ARTL, with a closing price of $1.60 as of September 26, 2018.

2018-10-05 · 9999999995-18-002562

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows EFFECT in the pre-IPO sequence.

Price $1.60 · 2,426,424 shares · Gross proceeds $0.00

Common Stock offered by Selling Stockholders · Exchange OTCQB · Ticker ARTL · Warrants held by selling stockholders exercisable for common stock · Selling stockholders only · Use of proceeds Selling stockholders' shares, no issuer proceeds

Artelo Biosciences, Inc. is registering 2,426,424 shares of common stock for sale by selling stockholders, including 1,213,212 shares from private placements and 1,213,212 shares via warrant exercises. The company, formerly focused on online commerce, has shifted to biosciences, particularly cannabinoid-based therapies. It holds licenses for NEOMED compound development and has undergone leadership changes, including CEO Gregory Gorgas. The offering follows a prior 424B3 supplement detailing quarterly financials and updated risk factors.

2018-09-27 · 0001640334-18-001830

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows S-1 and confirms the priced prospectus.

5,922,564 shares

Common Stock · Exchange OTCQB · Ticker ARTL · Warrants exercisable for 2,751,282 shares of common stock held by selling stockholders · Selling stockholders only · Use of proceeds Proceeds from warrant exercises, if any, are not specified

The current filing updates the prospectus to include the company's Quarterly Report on Form 10-Q for the period ended May 31, 2018. It details the sale of 5,922,564 shares of common stock by selling stockholders, including shares from warrant exercises and private placements. The company's common stock is quoted on the OTCQB, with a closing price of $1.27 as of July 26, 2018. The filing emphasizes the risks of investing in a speculative, early-stage biotechnology company with limited operating history and substantial doubt about its ability to continue as a going concern.

2018-07-27 · 0001640334-18-001471

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

First tracked pre-IPO filing for this issuer.

5,922,564 shares

Common Stock · Exchange OTCQB · Ticker ARTL · Up to 2,751,282 shares issuable upon exercise of warrants held by certain selling stockholders · Selling stockholders only · Use of proceeds Proceeds from share sales go to selling stockholders; no proceeds to issuer

Artelo Biosciences, Inc. is registering 5,922,564 shares of common stock for sale by existing stockholders, including 2,751,282 shares from warrant exercises and 3,171,282 shares from prior private placements. The company will not receive proceeds from these sales, which will be distributed via OTCQB or private transactions. The filing highlights the speculative nature of the investment, with risks tied to unproven therapies, regulatory hurdles, and reliance on partnerships. The company has shifted focus to cannabinoid-based treatments and holds licenses for NEOMED and Stony Brook University technologies.

2018-05-30 · 0001640334-18-001116

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1/A and marks the registration effective.

Artelo Biosciences, Inc. filed a Form S-1 registration statement for 5,922,564 shares of common stock, including 2,751,282 shares from warrant exercises and 3,171,282 shares from private placements. The offering is registered with the SEC, with shares to be sold by selling stockholders at $0.65 per share until quoted on the OTC Bulletin Board. The company’s stock is approved for quotation under the symbol ARTL on the OTC Pink. The prospectus highlights risks of investing in a speculative, early-stage biotechnology company with limited operating history and no revenue.

2018-05-29 · 9999999995-18-001358

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

Price $0.65 · 5,922,564 shares

Common Stock · Exchange OTC · Ticker ARTL · Up to 2,751,282 shares issuable upon exercise of warrants held by selling stockholders · Selling stockholders only · Use of proceeds Proceeds from warrant exercises, if any, will be used for general corporate purposes

Artelo Biosciences, Inc. (formerly Reactive Medical, Inc.) is a biotechnology company focused on developing cannabinoid-based therapeutic treatments. The company has undergone multiple name changes and strategic shifts, including licensing agreements with NEOMED and Stony Brook University for drug development. It has also conducted private placements and restructured its leadership and board composition. The current filing relates to the sale of 5,922,564 shares of common stock by selling stockholders, including warrants and previously issued shares.

2018-05-14 · 0001640334-18-000945

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

Price $0.65 · 5,922,564 shares

Common Stock · Exchange OTCPINK · Ticker ARTL · Warrants held by selling stockholders exercisable into 2,751,282 shares · Selling stockholders only · Use of proceeds No proceeds to the company from the sale of these securities

Artelo Biosciences, Inc. (formerly Reactive Medical, Inc.) is a biotechnology company focused on developing cannabinoid-based therapeutic treatments. The company has undergone multiple name changes and strategic shifts, including licensing agreements with NEOMED and Stony Brook University for drug development. The current filing relates to an offering of 5,922,564 shares of common stock, including shares from private placements and warrants, to be sold by selling stockholders. The company's stock is quoted on the OTC Pink market under the symbol ARTL.

2018-04-17 · 0001640334-18-000750

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1 filing.

Price $1.49 · 5,922,564 shares

Common Stock · Exchange OTC · Ticker ARTL · Warrants exercisable for 2,751,282 shares of common stock · Selling stockholders only · Use of proceeds Proceeds from the sale of shares will go to the selling stockholders; no proceeds to the company · Flags warrants

Artelo Biosciences, Inc. is registering 5,922,564 shares of common stock for sale by selling stockholders, including 3,171,282 shares from private placements and 2,751,282 shares from warrant exercises. The company will not receive proceeds from these sales, which are intended to provide liquidity to existing shareholders. The filing includes updates to share numbers, pricing, and registration fees compared to the prior S-1, along with details about the company's focus on cannabinoid-based therapies and drug development. The prospectus highlights risks related to the company's early-stage operations and reliance on key personnel.

2018-03-21 · 0001640334-18-000507

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows EFFECT in the pre-IPO sequence.

Price $2.20 · 5,618,162 shares

Common stock offered by selling stockholders and underlying warrants · Exchange OTC · Ticker ARTL · 2,749,081 shares of common stock underlying warrants · Selling stockholders only · Use of proceeds No proceeds to the issuer; selling stockholders are offering shares · Flags warrants · Underwriters self-underwritten

Artelo Biosciences, Inc. (formerly Knight Knox Development Corp.) transitioned from an online business model to a biotechnology focus, licensing cannabinoid-based therapeutic patents and rebranding. The S-1 registers 5,618,162 shares of common stock for sale by existing stockholders, including warrants, with no proceeds to the company. The filing reflects leadership changes, expanded operations in Europe, and a shift toward drug development, particularly involving the NEOMED compound.

2018-01-29 · 0001640334-18-000191

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1/A and marks the registration effective.

The filing confirms the effectiveness of Knight Knox Development Corp.'s S-1 registration statement for an initial public offering (IPO) of 8,000,000 shares of common stock at $0.01 per share. The company, a development-stage entity with minimal operations, intends to use proceeds for general corporate purposes. No public market exists for its shares, and it faces risks including shell company status, lack of trading liquidity, and auditor doubts about its ability to continue as a going concern.

2015-01-28 · 9999999995-15-000221

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

Price $0.01 · 8,000,000 shares · Gross proceeds $80,000

Common Stock $0.001 par value · Exchange OTCBB · Use of proceeds working capital · Underwriters self-underwritten

Knight Knox Development Corp. is a development stage company seeking to raise $80,000 through the sale of 8,000,000 shares of common stock at $0.01 per share. The offering is self-underwritten by the sole officer, James Manley, with no minimum share requirements. The company has no operating history, minimal assets, and is classified as a shell company. It aims to secure OTCBB quotation but lacks a market maker. Auditors have expressed substantial doubt about its ability to continue as a going concern.

2015-01-23 · 0001557240-15-000043

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1 filing.

Price $0.01 · 8,000,000 shares · Gross proceeds $80,000

Common Stock $0.001 par value · Exchange OTCBB · Use of proceeds Working capital · Underwriters self-underwritten

Knight Knox Development Corp. is conducting an initial public offering (IPO) of 8,000,000 shares of common stock at $0.01 per share. The company is a development-stage entity with minimal operations and no current trading market for its shares. The offering is self-underwritten by the sole officer and director, James Manley, with no minimum fundraising requirements. Proceeds will be used for general corporate purposes, and the company has not yet arranged for market makers to quote its shares on the OTCBB. The offering period is 270 days, extendable by directors.

2014-12-24 · 0001557240-14-000797

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

First tracked pre-IPO filing for this issuer.

Price $0.01 · 8,000,000 shares · Gross proceeds $80,000

Common Stock · Exchange OTCBB · Use of proceeds working capital · Flags self_underwritten, best_efforts · Underwriters self-underwritten

Knight Knox Development Corp. is a development-stage company registering 8,000,000 shares of common stock at $0.01 per share in an initial public offering (IPO). The offering is self-underwritten by the company's sole officer, James Manley, with no minimum share requirements. The company has minimal operations, no public market for its shares, and relies on a single individual for sales. Proceeds will fund business operations, but there is no guarantee of successful fundraising or liquidity. Auditors expressed substantial doubt about the company's ability to continue as a going concern.

2014-10-08 · 0001557240-14-000578

ARTELO BIOSCIENCES, INC.

Filing Timeline

14 comparable deals

Recent News